Has Renelle Lim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,407 in general payments to Renelle Lim, MD across 53 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Renelle Lim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Renelle Lim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Renelle Lim, MD

Ophthalmic Plastic and Reconstructive Surgery · Sarasota, FLNPI 1073821856

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Amgen at 41.2% of the total. That places this record below the midpoint for ophthalmic plastic and reconstructive surgery clinicians in FL, where the typical reported total is $1,956.

$2,407in general payments, 2019–2025

Across 53 payments — averaging $45.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$992
Smith+Nephew$276
Johnson & Johnson Vision Care, Inc.$265
Axogen$152
Idorsia Pharmaceuticals US Inc$122
Organogenesis Inc.$99
plus $500 from 10 others

What the payments were for

Food & beverage$2,39299%
Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	23	$992
Smith+Nephew	6	$276
Johnson & Johnson Vision Care, Inc.	2	$265
Axogen	2	$152
Idorsia Pharmaceuticals US Inc	1	$122
Organogenesis Inc.	4	$99
Sight Sciences, Inc.	1	$93
Genentech USA, Inc.	1	$80
Mimedx Group, Inc.	3	$69
Convatec Inc.	2	$69
Tarsus Pharmaceuticals, Inc.	2	$66
Sun Pharmaceutical Industries Inc.	2	$48
Biotissue Holdings Inc.	1	$24
AbbVie	1	$22
Sanofi-aventis U.S. LLC	1	$15
Merz North America, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEPEZZA$420
Acuvue$265
Grafix$126
GRAFIX PL$126
QUVIVIQ$122

How this compares

$2,407 in reported general payments places this provider in the 50th percentile of 37 ophthalmic plastic and reconstructive surgery providers in Florida.

See all ophthalmic plastic and reconstructive surgery providers in Florida →

Medicare billing

Part B allowed, 2024

$311,598

Medicare patients

395

Services billed

1,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ErythromycinErythromycin Base	321	$3,174
Doxycycline Monohydrate	88	$844
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	79	$708
Cefadroxil	105	$525
Tobramycin-DexamethasoneTobramycin/Dexamethasone	13	$514
Minocycline Hcl	32	$296
ValacyclovirValacyclovir Hcl	36	$212
Doxycycline Hyclate	13	$195
Methylprednisolone	25	$134
SsdSilver Sulfadiazine	11	$76
Acetaminophen-CodeineAcetaminophen With Codeine	12	$25

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Sarasota

Karen ChapmanSarasota$2K
John FezzaVenice$3.6M
Wendy LeeMiami$616K
Jennifer MurdockMiami$316K
Ana VictoriaMiami$130K
Keshini ParbhuWindermere$102K
Sara WesterMiami$78K
Robert ApplebaumLakeland$39K
Yasaman MohadjerSt Petersburg$6K
William MackTampa$5K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →